Green Light Photodynamic Therapy In the Human Bladder

Nseyo, Unyime O.; Merrill, Daniel C.; Lundahl, Scott L.

doi:10.1089/clm.1993.11.247

Cited by 14 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TookadÒ presents also an absorption peak in the green (538 nm), allowing the use of irradiation at wavelength presenting a lower tissue penetration (42) and opening the field of applications to superficial cancers in hollow organs, with a major reduction of the risk of fistulae or stenoses (43). Indeed, PDT at a shorter wavelength is already used to selectively treat a certain thickness of tissue in the cases of superficial bladder tumors (44) and for early cancers of the esophagus (43).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Photosensitizer Tookad® for Photodynamic Therapy on the Syrian Golden Hamster Cheek Pouch Model: Light Dose, Drug Dose and Drug–light Interval Effects¶

Borle¹,

Radu²,

Monnier³

et al. 2003

Photochem Photobiol

View full text Add to dashboard Cite

We have evaluated the efficacy of the new photosensitizer (PS) Tookad in photodynamic therapy (PDT) in vivo. This PS is a palladium-bacteriopheophorbide presenting absorption peaks at 762 and 538 nm. The light dose, drug dose and drug injection-light irradiation interval (DLI), ranging between 100 and 300 J/cm2, 1 and 5 mg/kg and from 10 to 240 min, respectively, were varied, and the response to PDT was analyzed by staging the macroscopic response and by the histological examination of the sections of the irradiated cheek pouch. The level of PDT response, macroscopically and histologically, shows a strong dependence on the DLI, light dose and drug dose at the applied conditions in the normal hamster cheek pouch. A decay of the tissular response with increasing DLI is observed corresponding to a time of half-maximum response ranging from 10 to 120 min, depending on drug dose and light dose. The tissues affected at the lowest doses are predominantly the vascularized diffuse connective tissue situated between the inner and outer striated muscle (SM) layers as well as these muscle layers themselves. The highest response at the shortest DLI and the absence of a measurable response at DLI longer than 240 min at 300 J/cm2 and drug dose of 5 mg/kg are characteristics of a predominantly vascular effect of this PS. This observation suggests that Tookad could be effective in PDT of vascularized lesions or pathologies associated with the proliferation of neovessels.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the Photosensitizer Tookad® for Photodynamic Therapy on the Syrian Golden Hamster Cheek Pouch Model: Light Dose, Drug Dose and Drug–light Interval Effects¶

Borle¹,

Radu²,

Monnier³

et al. 2003

Photochem Photobiol

View full text Add to dashboard Cite

show abstract

“…Tookad® presents also an absorption peak in the green (538 nm), allowing the use of irradiation at wavelength presenting a lower tissue penetration (42) and opening the field of applications to superficial cancers in hollow organs, with a major reduction of the risk of fistulae or stenoses (43). Indeed, PDT at a shorter wavelength is already used to selectively treat a certain thickness of tissue in the cases of superficial bladder tumors (44) and for early cancers of the esophagus (43).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Photosensitizer Tookad® for Photodynamic Therapy on the Syrian Golden Hamster Cheek Pouch Model: Light Dose, Drug Dose and Drug-light Interval Effects¶

Borle

Radu

Monnier

et al. 2007

Photochemistry and Photobiology

View full text Add to dashboard Cite

We have evaluated the efficacy of the new photosensitizer (PS) Tookad® in photodynamic therapy (PDT) in vivo. This PS is a palladium‐bacteriopheophorbide presenting absorption peaks at 762 and 538 nm. The light dose, drug dose and drug injection–light irradiation interval (DLI), ranging between 100 and 300 J/cm2, 1 and 5 mg/kg and from 10 to 240 min, respectively, were varied, and the response to PDT was analyzed by staging the macroscopic response and by the histological examination of the sections of the irradiated cheek pouch. The level of PDT response, macroscopically and histologically, shows a strong dependence on the DLI, light dose and drug dose at the applied conditions in the normal hamster cheek pouch. A decay of the tissular response with increasing DLI is observed corresponding to a time of half‐maximum response ranging from 10 to 120 min, depending on drug dose and light dose. The tissues affected at the lowest doses are predominantly the vascularized diffuse connective tissue situated between the inner and outer striated muscle (SM) layers as well as these muscle layers themselves. The highest response at the shortest DLI and the absence of a measurable response at DLI longer than 240 min at 300 J/cm2 and drug dose of 5 mg/kg are characteristics of a predominantly vascular effect of this PS. This observation suggests that Tookad® could be effective in PDT of vascularized lesions or pathologies associated with the proliferation of neovessels.

show abstract

“…These complications were associated with excessive light doses and nonuniform light delivery in the early studies. Nseyo et al showed that, for standardized protocols using lower drug and light dose [53], or for illumination with less penetrating light of 514 nm, good tumor response rates could be achieved for superficial lesions without transmural bladder injury or treatment-related morbidity [54]. Whole-bladder PDT with green light and proper dosimetry remains an attractive treatment option for carcinoma in situ (CIS), although this has not been fully evaluated.…”

Section: Bladder Cancermentioning

confidence: 99%

Photodynamic Therapy in Oncology

Triesscheijn¹,

et al. 2006

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is increasingly being recognized as an attractive, alternative treatment modality for superficial cancer. Treatment consists of two relatively simple procedures: the administration of a photosensitive drug and illumination of the tumor to activate the drug. Efficacy is high for small superficial tumors and, except for temporary skin photosensitization, there are no long-term side effects if appropriate protocols are followed. Healing occurs with little or no scarring and the procedure can be repeated without cumulative toxicity. Considering the efficacy and lack of long-term toxicity of PDT, and the fact that the first treatment of cancer with PDT was done more than 100 years ago, one might expect that this treatment had already become an established therapy. However, PDT is currently offered in only a few selected centers, although it is slowly gaining acceptance as an alternative to conventional cancer therapies. Here, we show the developmental steps PDT underwent and summarize the current clinical applications. The data show that, when properly used, PDT is an effective alternative treatment option in oncology. The

show abstract

Green Light Photodynamic Therapy In the Human Bladder

Cited by 14 publications

References 7 publications

Evaluation of the Photosensitizer Tookad® for Photodynamic Therapy on the Syrian Golden Hamster Cheek Pouch Model: Light Dose, Drug Dose and Drug–light Interval Effects¶

Evaluation of the Photosensitizer Tookad® for Photodynamic Therapy on the Syrian Golden Hamster Cheek Pouch Model: Light Dose, Drug Dose and Drug–light Interval Effects¶

Evaluation of the Photosensitizer Tookad® for Photodynamic Therapy on the Syrian Golden Hamster Cheek Pouch Model: Light Dose, Drug Dose and Drug-light Interval Effects¶

Photodynamic Therapy in Oncology

Contact Info

Product

Resources

About